A Randomized, Double-blind, Placebo-controlled Prospective Crossover Trial Investigating the Efficacy and Safety of the Treatment With Bupropion in Patients With Apathy in Huntington's Disease (Action-HD)

NCT01914965 Phase 2 COMPLETED

The influence of bupropion compared to placebo on the change of apathy as quantified by the apathy evaluation scale (AES-I, where I \[informant\] is a friend or family member familiar with the daily activities of the subject) in patients with HD after ten (10) weeks of treatment.

Details

Lead sponsor	Charite University, Berlin, Germany
Phase	Phase 2
Status	COMPLETED
Enrolment	40
Start date	2012-06
Completion	2014-05

Conditions

• Apathy
• Huntington's Disease

Interventions

• Bupropion
• Placebo

Primary outcomes

• Apathy Evaluation Scale (AES-I) — 10 weeks
  The influence of Bupropion compared to placebo on the change of apathy as quantified by the apathy evaluation scale (AES-I, where I \[informant\] is a friend or family member familiar with the daily activities of the subject) in patients with HD after ten weeks of treatment.

Countries

Germany